Appili Therapeutics Inc. (APLI.TO)

0.0250 0.0000 (0.00%) At close: 03:00PM EDT

Appili Therapeutics Inc.

#21-1344 Summer Street
Halifax, NS B3H 0A8
Canada
902-442-4655
https://appilitherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Donald D. Cilla Jr., M.B.A., Pharmd	CEO, President & Director	588.6k	N/A	N/A
Mr. Kenneth G. Howling	Chief Financial Officer	481.94k	N/A	N/A
Dr. Gary S. Nabors Ph.D.	Chief Development Officer	540.01k	N/A	N/A
Dr. Carl Gelhaus Ph.D.	Director of Non-Clinical Research	296.66k	N/A	N/A
Mr. Arthur Baran	Director of New Product Development	308.7k	N/A	N/A

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Corporate Governance

Appili Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.